Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19

Summary

This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.

Timeline

Start

2020-04-20

Primary completion

2020-06-30

Completion

2023-07

Outcome

Outcome not reported

Stopped: “Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.”

Drugs

Indications